In the Claims:

Cancel Claims 1 – 47 and 58 – 83.

1. – 47 (Cancelled)

48. (Original) A commercial process of producing neohesperidin comprising the steps of:

(a) obtaining hesperidin;

(b) treating said hesperidin with a hesperidinase, thereby obtaining hesperetin-7-glucoside; and

(c) treating said hesperetin-7-glucoside with a flavanone-7-O-glucoside-2"-O-rhamnosyl-transferase in the presence of activated rhamnose, thereby obtaining neohesperidin.

49. (Original) The commercial process of claim 48, wherein said activated rhamnose is selected from the group consisting of UDP-rhamnose or dTDP-rhamnose.

50. (Original) The commercial process of claim 48, wherein said hesperidinase is immobilized on a solid support, whereas said hesperidin is treated with said hesperidinase while passing over said solid support.

51. (Original) The commercial process of claim 48, wherein said treatment of hesperetin-7-glucoside with a flavanone-7-*O*-glucoside-2"-*O*-rhamnosyl-transferase in presence of activated rhamnose of step (c) is effected *in vivo* by a cell genetically modified to overexpress said flavanone-7-*O*-glucoside-2"-*O*-rhamnosyl-transferase, which said cell is producing activated rhamnose and is capable of intake of said hesperetin-7-glucoside.

52. (Original) The commercial process of claim 51, further comprising the step of extracting said neohesperidin from said cell.

53. (Original) A commercial process of producing neohesperidin dihydrochalcone comprising the steps of:

(a) obtaining hesperidin;

(b) treating said hesperidin with a hesperidinase, thereby obtaining hesperetin-7-glucoside;

(c) treating said hesperetin-7-glucoside with a flavanone-7-*O*-glucoside-2"-*O*-rhamnosyl-transferase in the presence of activated rhamnose, thereby obtaining neohesperidin;

(d) treating said neohesperidin with an alkali, thereby obtaining neohesperidin chalcone; and

(e) reducing said neohesperidin chalcone, thereby obtaining neohesperidin dihydrochalcone

54. (Original) The commercial process of claim 53, wherein said activated rhamnose is selected from the group consisting of UDP-rhamnose or dTDP-rhamnose.

55. (Original) The commercial process of claim 53, wherein said hesperidinase is immobilized on a solid support, whereas said hesperidin is treated with said hesperidinase while passing over said solid support.

56. (Original) The commercial process of claim 53, wherein said treatment of hesperetin-7-glucoside with a flavanone-7-*O*-glucoside-2"-*O*-rhamnosyl-transferase in presence of activated rhamnose of step (c) is effected *in vivo* by a cell genetically modified to overexpress said flavanone-7-*O*-glucoside-2"-*O*-rhamnosyl-transferase, which said cell is producing activated rhamnose and is capable of intake of said hesperetin-7-glucoside.

57. (Original) The commercial process of claim 56, further comprising the step of extracting said neohesperidin from said cell prior to treating said neohesperidin with said alkali.

58. – 83. (Cancelled)

Please replace the Sequence Listing with that attached herewith.

Enclosed please find a nucleotide and/or amino acid listing in a computer readable and paper forms; and

Statements

The content of the paper and computer readable form are the same and include no new matter.